title

تاثیر آتورواستاتین در بیماران مبتلا به بیماری انسدادی مزمن ریه ناشی از گاز سولفور موستارد : یک کارآزمائی بالینی

قبادی مراللو, حسن ، محمدزاده لاری, شهرزاد ، پورفرضی, فرهاد ، محمودپور, افسون ، قانعی, مصطفی (1392) تاثیر آتورواستاتین در بیماران مبتلا به بیماری انسدادی مزمن ریه ناشی از گاز سولفور موستارد : یک کارآزمائی بالینی. Journal of Research in Medical Sciences ــ 19 (2). ص.ص.99-105. شاپا 1735-1995

[img]
پیش نمایش
متنی - نسخه چاپ شده
582kB

آدرس اینترنتی رسمی : http://jrms.mui.ac.ir/index.php/jrms/article/view/...


عنوان انگليسي

The effects of atorvastatin on mustard gas exposed patients with chronic obstructive pulmonary disease: A randomized controlled trail.

خلاصه انگلیسی

Background: Statins have anti-inflammatory effects in patients with chronic obstructive pulmonary disease (COPD). This study designed to evaluate the effects of atorvastatin on serum highly sensitive C-reactive protein (hs-CRP) and pulmonary function in sulfur mustard exposed patients with COPD. Materials and Methods: Fifty patients with chronic obstructive pulmonary disease due to sulfur mustard and high serum hs-CRP entered in this study. Participants were randomized to receive 40 mg atorvastatin or placebo in a double-blind clinical trial. Forty-five patients completed the study (n = 23 atorvastatin and n = 22 placebo). Pulse oximetry (SpO2), pulmonary function test (PFT), and 6 min walk distance test (6MWD) was measured. COPD assessment test (CAT) and St.George’s respiratory questionnaire (SGRQ) were also completed by patients at the beginning of trial and after 9 weeks of prescription of 40 mg/day atorvastatin or placebo. At fourth week, SpO2, PFT, and 6MWD were again measured. After 9 weeks serum hs-CRP was re-measured. Results: There was no significant difference between atorvastatin and the placebo group in SpO2, FEV1, and 6MWD after fourth week (P = 0.79, P = 0.12, P = 0.12, respectively). The difference between baseline and ninth week was calculated for two groups of trial and control in term of serum hs-CRP, SpO2, FEV1, and 6MWD. Significant improvement was not observed between two groups in above mentioned variables (P = 0.35, P = 0.28, P = 0.94, P = 0.43, respectively). However, the quality of life was improved by administration of atorvastatin using the CAT score (P < 0.001) and SGRQ total score (P = 0.004). Conclusion: Atorvastatin does not alter serum hs-CRP and lung functions but may improve quality of life in SM-injured patients with COPD.

نوع سند :مقاله
زبان سند : انگلیسی
نویسنده اول :حسن قبادی مراللو
نویسنده مسئول :شهرزاد محمدزاده لاری
نویسنده :فرهاد پورفرضی
نویسنده :افسون محمودپور
نویسنده :مصطفی قانعی
اطلاعات اضافی :Impact Factor: 0.684 Indexing in : ISI , PubMed , Scopus , Chemical abstract
کلید واژه ها:آتورواستاتین, سولفور موستارد, COPD, hs-CRP
کلید واژه ها (انگلیسی):Atorvastatin, COPD, hs-CRP, sulfur mustard
موضوعات :QV فارماکولوژی
W حرفه پزشکی
WF سیستم تنفسی
بخش های دانشگاهی :دانشكده پزشكي > گروه اطفال ، پزشکی اجتماعی
دانشكده پزشكي > گروه داخلی ، قلب ، عفونی
کد شناسایی :5471
ارائه شده توسط : دکتر حسن قبادی
ارائه شده در تاریخ :18 اسفند 1392 14:18
آخرین تغییر :12 بهمن 1393 10:11

فقط پرسنل کتابخانه صفحه کنترل اسناد

Document Downloads

More statistics for this item...